TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from NewAmsterdam Pharma Company ( (NAMS) ) is now available.
On November 5, 2025, NewAmsterdam Pharma announced its third-quarter financial results and provided a corporate update. The company reported a significant regulatory milestone with the European Medicines Agency’s acceptance of marketing authorization applications for obicetrapib and its fixed-dose combination with ezetimibe. Despite a decrease in revenue and an increase in net loss compared to the previous year, NewAmsterdam continues to advance its clinical development strategy and build global infrastructure to support the potential launch of obicetrapib. The company also highlighted its ongoing trials and upcoming milestones, emphasizing its commitment to providing a differentiated therapy in the cardiovascular market.
The most recent analyst rating on (NAMS) stock is a Hold with a $36.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
The overall stock score for NewAmsterdam Pharma Company is primarily influenced by its strong technical momentum, which is a positive indicator for short-term performance. However, the financial performance is hindered by operational losses and negative cash flows, typical of the biotech industry. The valuation is impacted by the lack of profitability and absence of dividends, which are significant considerations for long-term investors.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (LDL-C), particularly for those for whom existing therapies are not sufficiently effective or well-tolerated.
Average Trading Volume: 1,056,259
Technical Sentiment Signal: Buy
Current Market Cap: $4.11B
For a thorough assessment of NAMS stock, go to TipRanks’ Stock Analysis page.